CD14 and neoplasm: Additionally, PF-04136309, a small molecule CCR2 inhibitor, depletes CCR-2+/CD14+ monocytes and macrophages from the primary pancreatic tumor and premetastatic liver resulting in enhanced anti-tumor immunity, decreased tumor growth, and reduced metastasis in mice model [39].